Literature DB >> 33561604

Interstitial lung disease and obstructive sleep apnea.

Yet H Khor1, Christopher J Ryerson2, Shane A Landry3, Mark E Howard4, Thomas J Churchward5, Bradley A Edwards3, Garun S Hamilton6, Simon A Joosten7.   

Abstract

Obstructive sleep apnea (OSA) is one of the most common comorbidities in patients with interstitial lung disease (ILD). Growing evidence highlights the significance of sleep disturbance on health outcomes in this population. The relationships between ILD and OSA are complex and possibly bidirectional, with multiple mechanisms postulated for the pathogenic and physiologic links. This review synthesizes current evidence and hypotheses regarding different aspects of the relationships between ILD and OSA, emphasizing the interactions between epidemiology, pathogenesis, and pathophysiology.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Interstitial lung disease; Obstructive sleep apnea; Pulmonary fibrosis; Sleep

Year:  2021        PMID: 33561604     DOI: 10.1016/j.smrv.2021.101442

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  3 in total

Review 1.  Obstructive Sleep Apnea as a Risk Factor for COVID-19 Severity-The Gut Microbiome as a Common Player Mediating Systemic Inflammation via Gut Barrier Dysfunction.

Authors:  Saif Mashaqi; Rekha Kallamadi; Abhishek Matta; Stuart F Quan; Salma I Patel; Daniel Combs; Lauren Estep; Joyce Lee-Iannotti; Charles Smith; Sairam Parthasarathy; David Gozal
Journal:  Cells       Date:  2022-05-06       Impact factor: 7.666

Review 2.  Cough in Idiopathic Pulmonary Fibrosis.

Authors:  Jennifer Mann; Nicole S L Goh; Anne E Holland; Yet Hong Khor
Journal:  Front Rehabil Sci       Date:  2021-10-18

Review 3.  The Association between Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.

Authors:  Filip Franciszek Karuga; Piotr Kaczmarski; Bartosz Szmyd; Piotr Białasiewicz; Marcin Sochal; Agata Gabryelska
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.